Formononetin exhibits anticancer activity in gastric carcinoma cell and regulating miR-542-5p

Wei-Song Wang1, Can-Song Zhao2

  • 1Department of General Surgery, Zhuji Central Hospital, Zhuji, China.

Insights

Formononetin effectively inhibits gastric carcinoma (GC) growth and spread by reducing cell viability and migration. This natural compound also downregulates the oncogene microRNA-542-5p (miR-542-5p), offering a potential therapeutic strategy for GC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Formononetin is known for anti-neoplastic effects in colon and breast cancers.
  • The role of formononetin in gastric carcinoma (GC) remains largely unexplored.
  • Gastric carcinoma exhibits aggressive growth and metastatic potential.

Purpose of the Study:

  • To investigate the anticancer effects of formononetin on gastric carcinoma cells.
  • To elucidate the underlying molecular mechanisms, including the role of microRNA-542-5p (miR-542-5p).
  • To evaluate formononetin's efficacy in preclinical models of GC.

Main Methods:

  • Cell viability assays on GC cell lines (SGC-7901, MGC-803).
  • Migration and invasion assays for GC cells treated with formononetin.
  • In vivo studies using a xenograft model to assess anticancer effects.
  • Analysis of microRNA-542-5p (miR-542-5p) expression in GC.

Main Results:

  • Formononetin significantly reduced the viability of SGC-7901 and MGC-803 GC cell lines.
  • Formononetin suppressed the migration and invasion capabilities of GC cells in vitro.
  • Anticancer effects were confirmed in a xenograft model.
  • Upregulation of microRNA-542-5p (miR-542-5p) was observed in GC, and it may mediate formononetin's activity.

Conclusions:

  • Formononetin demonstrates potent inhibitory effects on gastric carcinoma cell growth and aggressiveness.
  • The compound's action involves the modulation of microRNA-542-5p (miR-542-5p).
  • Formononetin presents a promising therapeutic candidate for gastric carcinoma treatment.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.5K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.3K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.2K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.3K